Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X5SD
|
|||
| Former ID |
DAP000012
|
|||
| Drug Name |
Disulfiram
|
|||
| Synonyms |
Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Approved | [1], [2] | |
| Therapeutic Class |
Alcohol Deterrents
|
|||
| Company |
Odyssey Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H20N2S4
|
|||
| Canonical SMILES |
CCN(CC)C(=S)SSC(=S)N(CC)CC
|
|||
| InChI |
1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
|
|||
| InChIKey |
AUZONCFQVSMFAP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 97-77-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4833, 86944, 604564, 841760, 3134612, 7343344, 7847199, 8151985, 10321282, 10538921, 11111859, 11111860, 11363904, 11366466, 11369028, 11371250, 11374034, 11377190, 11466125, 11467245, 11484927, 11485729, 11488992, 11490221, 11492043, 11494824, 11533044, 11533307, 14720391, 14751553, 17405720, 22390447, 22391499, 24278722, 24888757, 26611716, 26680072, 26719650, 26747681, 26747682, 26753660, 26753661, 29222259, 46386898, 46487911, 46506008, 47216881, 47736606, 47810875, 48110561
|
|||
| ChEBI ID |
CHEBI:4659
|
|||
| ADReCS Drug ID | BADD_D00695 | |||
| SuperDrug ATC ID |
N07BB01; P03AA04
|
|||
| SuperDrug CAS ID |
cas=000097778
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Erysipelatoclostridium ramosum was decreased by Disulfiram (adjusted p-values: 1.30E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty aldehyde dehydrogenase (ALDH3A2) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7168). | |||
| REF 2 | Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep. 2006 Oct;8(5):383-8. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.